Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Product

Cyclophosphamide

Aliases
2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida (51 other aliases)
Name
Cyclophosphamide
FDA Approved
Yes

233 clinical trials

27 organizations

1 drug

2 abstracts

294 indications

1 document

Indication
Diffuse Intrinsic Pontine Glioma
Indication
Cancer
Indication
Chronic Lymphocytic Leukemia
Indication
Leukemia
Indication
Ewing Sarcoma
Indication
Solid Tumors
Indication
Rhabdoid Tumor
Indication
Rhabdomyosarcoma
Indication
Neuroblastoma
Indication
Medulloblastoma
Indication
Chronic lymphocytic leukemia/small lymphocytic lymphoma
Indication
Non-Hodgkin lymphoma
Indication
mantle cell lymphoma
Indication
Follicular Lymphoma
Indication
Diffuse Large B-cell Lymphoma
Indication
Indolent B-Cell Non-Hodgkin Lymphoma
Indication
Diffuse Large B-Cell Lymphoma
Indication
Refractory Cancer
Indication
Refractory Neoplasm
Indication
Pediatric Cancer
Indication
Refractory Tumor
Indication
Pediatric Brain Tumor
Indication
Neuroblastoma Recurrent
Indication
Lymphoma
Indication
Pediatric Meningioma
Indication
Refractory aggressive B-cell lymphoma
Indication
Mantle Cell Lymphoma
Indication
Triple-negative Breast Cancer
Indication
Breast Cancer
Indication
Solid Tumor
Indication
Adult
Indication
Triple-Negative Breast Cancer
Indication
Colorectal Cancer
Indication
Hepatocellular Carcinoma
Indication
Osteosarcoma
Indication
Ovarian Cancer
Indication
Stomach Cancer
Indication
Lung Cancer
Indication
Melanoma
Indication
Relapsed oropharyngeal squamous cell carcinoma
Indication
Oropharyngeal Squamous Cell Carcinoma
Indication
Cervical Cancer
Indication
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Indication
Relapsed/Refractory B-Cell Lymphoma
Indication
Large B Cell Lymphoma
Indication
Non-Hodgkin Lymphoma
Indication
Relapsed/Refractory Large B-cell Lymphoma
Indication
Human Papillomavirus (HPV) 16+ Relapsed/Refractory Cancer
Indication
Oral Squamous Cell Carcinoma
Indication
Oropharyngeal Cancer
Indication
Human Papillomavirus
Indication
Head and Neck Cancer
Indication
Head and Neck Squamous Cell Carcinoma
Indication
Squamous Cell Carcinoma of the Oropharynx
Indication
Metastatic
Indication
Head and Neck Cancer Metastatic
Indication
HPV-Related Squamous Cell Carcinoma
Indication
HPV-Related Mucosal Head and Neck Squamous Cell Carcinoma
Indication
Marginal Zone Lymphoma
Indication
Indolent Non-Hodgkin Lymphoma
Indication
triple-negative breast cancer
Indication
Synovial Sarcoma
Indication
Myxoid Liposarcoma
Indication
Diffuse Large B Cell Lymphoma
Indication
Multiple Myeloma
Indication
Hodgkin lymphoma
Indication
B-cell Non-Hodgkin Lymphoma
Indication
lymphoma
Indication
Non-Hodgkin
Indication
Relapsed Non-Hodgkin Lymphoma
Indication
B-Cell Non-Hodgkin Lymphoma
Indication
B-cell Lymphoma
Indication
B-cell non-Hodgkin's lymphoma
Indication
Lupus Nephritis
Indication
Relapsed and/or Refractory Multiple Myeloma
Indication
Mesothelioma
Indication
Mesothelioma, Malignant, Pleural
Indication
malignant
Indication
Peritoneal Mesothelioma
Indication
Ovarian Serous Adenocarcinoma
Indication
Pancreatic Cancer
Indication
Pancreatic adenocarcinoma
Indication
Ovarian Adenocarcinoma
Indication
Cholangiocarcinoma
Indication
Non Hodgkin's Lymphoma
Indication
Neutropenia
Indication
Fallopian tube cancer
Indication
Pancreatic Ductal Adenocarcinoma
Indication
Large B-Cell
Indication
Diffuse large B-cell lymphoma (DLBCL)
Indication
B-cell
Indication
Prostate Cancer
Indication
B-precursor Acute Lymphoblastic Leukemia
Indication
Large B-cell Lymphoma
Indication
Advanced Solid Tumor
Indication
B-cell Acute Lymphoblastic Leukemia
Indication
Lupus Erythematosus
Indication
Systemic
Indication
Pediatric
Indication
Adolescent
Indication
Relapsed or Refractory Small Lymphocytic Lymphoma
Indication
Systemic Lupus Erythematosus
Indication
Multiple Sclerosis
Indication
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Indication
B-cell lymphoma
Indication
Liver Transplant
Indication
High Grade B-cell Lymphoma
Indication
Primary Mediastinal B-cell Lymphoma
Indication
Transformed Lymphoma
Indication
Primary central nervous system lymphoma
Indication
Autoimmune Diseases
Indication
Acute Myeloid Leukemia
Indication
Acute Lymphoblastic Leukemia
Indication
Diffuse
Indication
Esophageal Cancer
Indication
Primary Mediastinal Large B Cell Lymphoma
Indication
Breast Neoplasms
Indication
cancer
Indication
Non-Small Cell Lung
Indication
Metastatic Non Small Cell Lung Cancer
Indication
Lung Adenocarcinoma
Indication
Myelodysplastic Syndromes
Indication
Follicular
Indication
Mantle Cell
Indication
Clear Cell Renal Cell Carcinoma
Indication
ANCA-associated Vasculitis
Indication
Blastic Plasmacytoid Dendritic Cell Neoplasm
Indication
Platinum-resistant Epithelial Ovarian Cancer
Indication
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Indication
Breast Neoplasm
Indication
Breast Cancer Metastatic
Indication
Gastrointestinal Epithelial Cancer
Indication
Gastrointestinal Neoplasms
Indication
Gastrointestinal Cancer
Indication
gastrointestinal
Indication
Gallbladder Cancer
Indication
Colon Cancer
Indication
Esophageal cancer
Indication
Squamous Cell Carcinoma
Indication
EGFR-positive solid tumor
Indication
Breast Cancer (HER2-positive)
Indication
Small Cell Lung Cancer
Indication
Renal Cell Carcinoma
Indication
NSCLC
Indication
Bladder Cancer
Indication
Microsatellite Instability
Indication
Merkel Cell Carcinoma
Indication
Follicular Lymphoma Grade 3B
Indication
High-grade B-cell lymphoma
Indication
Mediastinal B-Cell Diffuse Large Cell Lymphoma
Indication
Lymphocytic
Indication
Chronic
Indication
Relapsed Diffuse Large B-Cell Lymphoma
Indication
Transformed Follicular Lymphoma
Indication
Indolent Non-Hodgkin's Lymphoma
Indication
Locally Advanced Solid Tumor
Indication
Metastatic Cancer
Indication
HER2-positive Gastric Cancer
Indication
Gastric Esophageal Cancer
Indication
CD19-positive Relapsed or Refractory B-cell Malignancies
Indication
Precursor B-Cell Acute Lymphoblastic Leukemia
Indication
Triple Negative Breast Cancer
Indication
Advanced Hormone Receptor Positive/Endocrine Refractory Breast Cancer
Indication
Castration-Resistant Prostate Cancer
Indication
Platinum-Resistant Ovarian Cancer
Indication
T-lymphoblastic lymphoma
Indication
Acute Lymphocytic Leukemia
Indication
Acute Biphenotypic Leukemia
Indication
Acute Undifferentiated Leukemia
Indication
HER2-positive breast cancer
Indication
acute myeloid leukemia
Indication
Allogeneic
Indication
CAR-T
Indication
Protein Sequestration
Indication
Non-gene Edited
Indication
Metastatic Castration-resistant Prostate Cancer
Indication
Soft Tissue Sarcoma
Indication
Desmoplastic Small Round Cell Tumor
Indication
Extraskeletal Myxoid Chondrosarcoma
Indication
Angiomatoid Fibrous Histiocytoma
Indication
Clear Cell Sarcoma
Indication
Primary Pulmonary Myxoid Sarcoma
Indication
Myoepithelial Tumor
Indication
Sclerosing Epithelioid Fibrosarcoma
Indication
Fibromyxoid tumor
Indication
Risk Stratification
Indication
DOCK8 deficiency
Indication
Metastatic Solid Tumors
Indication
Graft-versus-host Disease
Indication
Ganglioneuroblastoma
Indication
Resectable Neuroblastoma
Indication
Leukemia, Acute Lymphoblastic
Indication
Accelerated Phase Chronic Myelogenous Leukemia
Indication
BCR-ABL1-positive
Indication
Acute myeloid leukemia with BCR-ABL1
Indication
Blast Phase Chronic Myelogenous Leukemia
Indication
Estrogen Receptor-Negative Breast Cancer
Indication
HER2/Neu Negative
Indication
Progesterone Receptor Negative
Indication
Progesterone Receptor Positive Tumor
Indication
Breast Cancer, Stage II
Indication
Stage IIA Breast Cancer
Indication
Triple-negative Breast Carcinoma
Indication
Stage II Breast Cancer
Indication
Stage IIB Breast Cancer
Indication
Adult Lymphoblastic Lymphoma
Indication
Leukemia, Burkitt
Indication
Burkitt Lymphoma
Indication
Childhood Lymphoblastic Lymphoma
Indication
Recurrent High Grade B-Cell Lymphoma
Indication
Burkitt Leukemia
Indication
Burkitt lymphoma
Indication
High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements
Indication
Lymphoblastic Lymphoma
Indication
Dyskeratosis Congenita
Indication
Aplastic Anemia
Indication
Sarcoma
Indication
Breast Carcinoma
Indication
Estrogen Receptor Negative
Indication
Stage 0 Breast Cancer
Indication
Breast Cancer AJCC Stage IA
Indication
Prognostic Stage IIB Breast Cancer AJCC v8
Indication
Triple-Negative Breast Carcinoma
Indication
EGFR gene mutation
Indication
Glioblastoma
Indication
MGMT promoter unmethylated glioblastoma
Indication
Non-Hodgkin Lymphoma, B Cell
Indication
Primary Myelofibrosis
Indication
Chronic Myelogenous Leukemia
Indication
Hematopoietic and Lymphoid Cell Neoplasm
Indication
Myelodysplastic Syndrome
Indication
Recurrent Follicular Lymphoma
Indication
Idiopathic Inflammatory Myopathies
Indication
Systemic Sclerosis
Indication
ANCA-Associated Vasculitis
Indication
Severe Combined Immunodeficiency
Indication
Omenn syndrome
Indication
Reticular Dysgenesis
Indication
Wiskott-Aldrich Syndrome
Indication
Bare Lymphocyte Syndrome
Indication
Common Variable Immunodeficiency
Indication
Chronic Granulomatous Disease
Indication
CD40L Deficiency
Indication
Hyper IgM Syndrome
Indication
X-linked lymphoproliferative syndrome
Indication
Hemophagocytic Lymphohistiocytosis
Indication
Griscelli Syndrome
Indication
Chediak-Higashi Syndrome
Indication
Langerhans Cell Histiocytosis
Indication
Advanced or Metastatic Solid Tumors
Indication
Mature B-cell Non-Hodgkin Lymphoma
Indication
T-cell/Histocyte-rich Large B-cell Lymphoma
Indication
Germinal Center B-cell Type (GCB)
Indication
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Indication
Philadelphia Chromosome Positive
Indication
Adult Acute Lymphoblastic Leukemia
Indication
Philadelphia chromosome-positive acute lymphoblastic leukemia
Indication
Multiple Myeloma in Relapse
Indication
Recurrent
Indication
Sickle Cell Disease
Indication
Hemoglobinopathies
Indication
acute lymphoblastic leukemia
Indication
Acute Myeloid Leukemia in Remission
Indication
Synovial
Indication
melanoma
Indication
Bladder Urothelial Carcinoma
Indication
Anaemia
Indication
Sickle Cell
Indication
GATA-2 deficiency
Indication
Immunodeficiency
Indication
MDS
Indication
Paraneoplastic Sensory Neuronopathy
Indication
Fanconi Anemia
Indication
T Cell Receptor Alpha/Beta Depletion
Indication
Bone Marrow Failure
Indication
Schimke immuno-osseous dysplasia
Indication
Cystinosis
Indication
Focal Segmental Glomerulosclerosis
Indication
Chronic Kidney Disease Stage 4
Indication
Stem Cell Transplantation
Indication
Metastasis
Indication
Allogeneic Hematopoietic Stem Cell Transplantation
Indication
Conditioning
Indication
Colorectal cancer
Indication
Biphenotypic/Undifferentiated Leukemia
Indication
Relapsed large B-cell lymphoma
Indication
B-Cell Acute Lymphoblastic Leukemia
Indication
Relapsed T-Cell Lymphoma
Indication
Waldenstrom Macroglobulinemia
Indication
Lymphoproliferative Disorders
Indication
Autoimmune Lymphoproliferative
Indication
Immune System Diseases
Indication
Primary T-cell Immunodeficiency Disorders
Indication
Hematopoietic Stem Cell Transplantation
Drug
cyclophosphamide
Clinical trial
Xarelto® for the Prevention of Stroke and Noncentral Nervous Systemic Embolism in Non-valvular Atrial Fibrillation With REnal Impairment in Taiwanese Population.
Status: Completed, Estimated PCD: 2022-11-15
Clinical trial
A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare The Efficacy and Safety of A Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/Bendamustine and Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL(17P) or TP53 Mutation
Status: Active (not recruiting), Estimated PCD: 2024-03-19
Clinical trial
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2026-02-01
Clinical trial
PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE®) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORS
Status: Active (not recruiting), Estimated PCD: 2024-06-24
Clinical trial
A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001 + STK-009) in Subjects With Relapsed or Refractory CD19+ Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2026-06-24
Clinical trial
Phase 1 Study of 9-ING-41, a Glycogen Synthase Kinase 3 Beta (GSK 3β) Inhibitor, as a Single Agent or With Irinotecan, Irinotecan Plus Temozolomide, or With Cyclophosphamide Plus Topotecan in Pediatric Patients With Refractory Malignancies.
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Phase 2 Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Rituximab in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)
Status: Completed, Estimated PCD: 2023-01-30
Clinical trial
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2023-11-26
Clinical trial
An Adaptive Randomized Neoadjuvant Two Arm Trial in Triple-negative Breast Cancer Comparing a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy (neoMono)
Status: Active (not recruiting), Estimated PCD: 2023-07-06
Clinical trial
Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T Cells (ACTolog® IMA101) Alone or in Combination With Atezolizumab in Patients With Relapsed and/or Refractory Solid Cancers
Status: Completed, Estimated PCD: 2021-09-22
Clinical trial
A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)
Status: Active (not recruiting), Estimated PCD: 2031-01-24
Clinical trial
A Multi-Center, Open-Label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-101 Monotherapy and AB-101 With Immunotherapy in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma of B-Cell Origin.
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Prospective, Open-Label, Randomized Study of Combination Therapy of MYOCET® Plus Cyclophosphamide and Trastuzumab Versus Free Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in Neoadjuvant Setting in Treatment-Naive Patients With HER2-Positive Breast Cancer
Status: Completed, Estimated PCD: 2015-09-17
Clinical trial
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
Status: Active (not recruiting), Estimated PCD: 2022-04-13
Clinical trial
A Phase I/II Clinical Trail of TC-E202 Targeting HPV16 E6 for Relapsed/Refractory to Standard Treatment or Metastatic Cervical Carcinoma
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Randomized Phase 2 Trial of Neoadjuvant and Adjuvant Therapy With the IRX 2 Regimen in Patients With Newly Diagnosed Stage II, III, or IVA Squamous Cell Carcinoma of the Oral Cavity
Status: Completed, Estimated PCD: 2022-02-28
Clinical trial
A Randomized, Open-Label, Phase 2 Study Evaluating Lymphodepletion With ALLO-647, Fludarabine, and Cyclophosphamide, vs. Fludarabine and Cyclophosphamide Alone, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase 3, Multicenter, Randomized, Open-Label Trial to Evaluate the Safety and Efficacy of Epcoritamab + Rituximab and Lenalidomide (R2) Compared to Chemoimmunotherapy in Previously Untreated Follicular Lymphoma (EPCORE™FL-2)
Status: Recruiting, Estimated PCD: 2028-10-05
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Comparing the Efficacy and Safety of Tafasitamab Plus Lenalidomide in Addition to R-CHOP Versus R-CHOP in Previously Untreated, High-intermediate and High-risk Patients With Newly-diagnosed Diffuse Large B-cell Lymphoma (DLBCL)
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Clinical trial
A Phase 1 Open-Label Dose-Escalation Study of the Safety of Adoptively Transferred Autologous CD8+ T Lymphocytes Targeting HPV-16 E6/E7, HPV-18 E6/E7 and Survivin in Patients With Relapsed or Refractory HPV-related Oropharyngeal Cancers
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Phase 1 Study Evaluating the Safety and Efficacy of HPV16 E7 T Cell Receptor Engineered T Cells (KITE-439) in HLA-A*02:01+ Subjects With Relapsed/Refractory HPV16+ Cancers
Status: Terminated, Estimated PCD: 2022-02-18
Clinical trial
A Phase 1/2 Open-label, Multicenter Study of Lenzilumab and Axicabtagene Ciloleucel in Subjects With Relapsed or Refractory Large B-cell Lymphoma (ZUMA-19)
Status: Terminated, Estimated PCD: 2021-03-16
Clinical trial
A Study to Evaluate the Safety and Immune Activity of PeptiCRAd-1 in Combination With Pembrolizumab in Patients With Injectable Solid Tumors in Indications Known to Express NY-ESO-1 and MAGE-A3
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA-7)
Status: Active (not recruiting), Estimated PCD: 2021-03-18
Clinical trial
A Phase 1 Study of FT522 in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2029-06-30
Clinical trial
Open-label, Randomized, Active-controlled, Multicenter, Phase III Clinical Trial to Compare the Efficacy and the Safety of AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Taxotere Versus AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Nanoxel M as Neoadjuvant Chemotherapy in Patients With Breast Cancer
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Clinical trial
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Completed, Estimated PCD: 2023-01-12
Clinical trial
A Phase 1b/2, Open Label, Dose Escalation Study to Evaluate Safety, Tolerability, Pharmacodynamics and Antitumor Activity of GX-I7 in Combination With Pembrolizumab in Subjects With Refractory or Relapsed (R/R) TNBC
Status: Completed, Estimated PCD: 2023-05-11
Clinical trial
A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Patients With B-Cell Non-Hodgkin Lymphoma
Status: Completed, Estimated PCD: 2023-10-12
Clinical trial
Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)
Status: Active (not recruiting), Estimated PCD: 2023-10-11
Clinical trial
A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase 1 Study to Evaluate the Efficacy and Safety of AB-101, an Allogeneic Cord Blood- Derived NK-Cell Therapy in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-06-07
Clinical trial
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2027-11-29
Clinical trial
A Phase 1/2 Single Arm Open-Label Clinical Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Status: Active (not recruiting), Estimated PCD: 2028-10-30
Clinical trial
A Phase 1 Open-Label, Multi-Center First in Human Study of TnMUC1-Targeted Genetically-Modified Chimeric Antigen Receptor T Cells in Patients With Advanced TnMUC1-Positive Solid Tumors and Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-12-02
Clinical trial
Open-label, Phase 1 Study of CD19 t-haNK as a Single Agent and in Combination With an IL-15 Superagonist (N-803) and Rituximab in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma.
Status: Not yet recruiting, Estimated PCD: 2026-03-15
Clinical trial
A Phase I/II Clinical Study of TC-N201 Injection for the Treatment of Advanced Solid Tumors With HLA-A2 Expression and Positive NY-ESO-1.
Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 2, Single-Arm, Open-Label, Multicenter Study of Brentuximab Vedotin in Combination With Cyclophosphamide, Doxorubicin (Hydroxydaunorubicin), Prednisone (CHP) in the Frontline Treatment of Chinese Patients With CD30-Positive (CD30+) Peripheral T-Cell Lymphomas (PTCL)
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Global Randomized Multicenter Phase 3 Trial to Compare the Efficacy and Safety of Lisocabtagene Maraleucel (JCAR017/BMS-986387) to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma (TRANSFORM FL)
Status: Not yet recruiting, Estimated PCD: 2031-10-16
Clinical trial
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After the Same-Day, Varying Dosing Time Schedules of Eflapegrastim Administration in Patients With Breast-Cancer Receiving Docetaxel and Cyclophosphamide
Status: Recruiting, Estimated PCD: 2024-07-31
Clinical trial
A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL (waveLINE)
Status: Recruiting, Estimated PCD: 2026-01-26
Clinical trial
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)
Status: Not yet recruiting, Estimated PCD: 2028-08-14
Clinical trial
A Phase 1b, Open Label, Global, Multicenter, Dose Determination, Randomized Dose Expansion Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of Iberdomide (CC-220) in Combination With R-CHOP-21 and CC-99282 in Combination With R-CHOP-21 for Subjects With Previously Untreated Aggressive B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-06-10
Clinical trial
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer
Status: Completed, Estimated PCD: 2021-02-05
Clinical trial
A Phase III, Multicenter, Randomized, Open-Label Study Comparing the Efficacy and Safety of Glofitamab (RO7082859) in Combination With Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Multicenter, Open-label, Adaptive Design Phase I Trial With Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With PSMA Peptide Target Module (TMpPSMA) for the Treatment of Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
Status: Terminated, Estimated PCD: 2024-03-28
Clinical trial
A Phase 2 Multicenter Study Evaluating the Safety and the Efficacy of KTE-X19 in Adult Japanese Subjects With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Status: Recruiting, Estimated PCD: 2027-05-01
Clinical trial
A Phase 3, Open Label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 × Anti-CD3 Bispecific Antibody, in Combination With CHOP (O-CHOP) Versus Rituximab in Combination With CHOP (R-CHOP) in Previously Untreated Participants With Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)
Status: Recruiting, Estimated PCD: 2028-09-18
Clinical trial
A Phase 2 Open-Label, Multicenter Study Evaluating The Safety And Efficacy of Axicabtagene Ciloleucel Concomitant With Prophylactic Steroids In Subjects With Relapsed Or Refractory Large B-Cell Lymphoma In The Outpatient Setting
Status: Active (not recruiting), Estimated PCD: 2026-03-01
Clinical trial
A Phase I/II, Single Arm, Multi-center Study Evaluating the Safety and Efficacy of HY004 in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
Status: Not yet recruiting, Estimated PCD: 2024-12-30
Clinical trial
A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2029-05-01
Clinical trial
A Phase 1 Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Moderate or Severe Systemic Lupus Erythematosus
Status: Recruiting, Estimated PCD: 2027-04-30
Clinical trial
CAMPFIRE: Children's and Young Adult Master Protocol for Innovative Pediatric Research
Status: Recruiting, Estimated PCD: 2026-05-01
Clinical trial
A 60 Month, Single-arm, Proof-of-concept Study to Induce Allogeneic Tolerance in Deceased Donor Liver Transplant Recipients Using Siplizumab, an Anti-CD2 Antibody in Combination With Cyclophosphamide and Splenectomy
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501A, an Anti-CD19 Allogeneic CAR T Cell Therapy, and ALLO-647, an Anti-CD52 Monoclonal Antibody, in Subjects With Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Phase Ib Study to Assess Safety and Preliminary Efficacy of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-NHL
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1 Study of FT819 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus
Status: Recruiting, Estimated PCD: 2027-09-30
Clinical trial
A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants With Relapsing Forms of Multiple Sclerosis (RMS) or Progressive Forms of Multiple Sclerosis (PMS)
Status: Recruiting, Estimated PCD: 2027-07-15
Clinical trial
A Phase Ib Study Evaluating Glofitamab (RO7082859) in Combination With Rituximab (R) or Obinutuzumab (G) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin (POLA) Plus Rituximab (R), Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Relapsed or Refractory Non-Hodgkin Lymphoma (R/R NHL) or in Participants With Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Active (not recruiting), Estimated PCD: 2024-10-30
Clinical trial
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)
Status: Recruiting, Estimated PCD: 2028-03-29
Clinical trial
A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 1/2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL).
Status: Completed, Estimated PCD: 2024-01-26
Clinical trial
A Phase 1 Open-label, Single Arm, Multicenter Study Evaluating the Safety and Efficacy of KITE-197 in Subjects With Relapsed or Refractory Large B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Acalabrutinib in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects ≤75 Years With Previously Untreated Non-GCB DLBCL
Status: Active (not recruiting), Estimated PCD: 2027-02-05
Clinical trial
A Phase I/II, Multicenter, Open-Label, Multi-Arm Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemias or Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-12-30
Clinical trial
A Phase 1 Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma-Delta (γδ) T Cells in Adults With Lupus Nephritis
Status: Not yet recruiting, Estimated PCD: 2026-12-01
Clinical trial
A Phase Ib Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Patients With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-06-19
Clinical trial
A Phase 1 Open-label, Multicenter Study Evaluating the Safety and Efficacy of KITE-363 or KITE-753, Autologous Anti-CD19/CD20 CAR T-cell Therapies, in Subjects With Relapsed and/or Refractory B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20x Anti-CD3 Bispecific Antibody, Combined With Chemotherapy Versus Rituximab Combined With Chemotherapy in Previously Untreated Participants With Follicular Lymphoma (OLYMPIA-2)
Status: Recruiting, Estimated PCD: 2030-01-24
Clinical trial
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2024-07-14
Clinical trial
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ACE1831, an Allogeneic CD20-conjugated Gamma Delta T-cell Therapy, in Adult Subjects With Relapsed/Refractory CD20-expressing B-cell Malignancies
Status: Recruiting, Estimated PCD: 2025-09-01
Clinical trial
A Multicenter, Open-label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Clinical trial
A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertuzumab in Combination With Standard (Neo)Adjuvant Treatment in Patients With Operable HER2+/HR+ Breast Cancer.
Status: Completed, Estimated PCD: 2020-07-14
Clinical trial
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-06-27
Clinical trial
A Phase II, Open-Label, Multicenter, Platform Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
Status: Active (not recruiting), Estimated PCD: 2028-05-30
Clinical trial
A Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (KarMMa-9)
Status: Recruiting, Estimated PCD: 2031-03-27
Clinical trial
A Randomized Multicenter, Double-Blind, Placebo-Controlled Comparison of Chemotherapy Plus Trastuzumab Plus Placebo Versus Chemotherapy Plus Trastuzumab Plus Pertuzumab as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2016-12-19
Clinical trial
A Phase 1/2 Trial (CheckCell-2) in Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Administering Tumor-Infiltrating Lymphocytes (TILs) in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Clinical trial
A Phase 1 Safety and Efficacy Study of ADI-001 Anti-CD20 CAR-engineered Allogeneic Gamma Delta (γδ) T Cells in Adults With B Cell Malignancies
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Multicentric, Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion (SDI) in Patients With Previously Untreated Advanced Follicular Lymphoma
Status: Completed, Estimated PCD: 2020-08-04
Clinical trial
A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With R-CHOP Compared to R-CHOP in Subjects With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Recruiting, Estimated PCD: 2027-01-31
Clinical trial
A Phase II Study Evaluating the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Phase 1b/2, Open-Label Trial to Evaluate Safety and Preliminary Efficacy of Epcoritamab As Monotherapy or Combined With Standard-of-Care Therapies in Chinese Subjects With B-Cell Non-Hodgkin Lymphoma
Status: Active (not recruiting), Estimated PCD: 2024-12-13
Clinical trial
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
Status: Recruiting, Estimated PCD: 2032-11-26
Clinical trial
A Phase 3, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib Versus Chemoimmunotherapy for Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Aberrations
Status: Recruiting, Estimated PCD: 2027-05-19
Clinical trial
A Phase 1 Multicenter Study Evaluating the Safety and Efficacy of ALLO-316 Following ALLO-647 Containing Conditioning Regimen in Subjects With Advanced or Metastatic Clear Cell Renal Cell Carcinoma
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase III Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Neoadjuvant Anthracycline/Nab-Paclitaxel-Based Chemotherapy Compared With Placebo and Chemotherapy in Patients With Primary Invasive Triple-Negative Breast Cancer
Status: Completed, Estimated PCD: 2020-04-03
Clinical trial
A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase I/II Trial to Study Efficacy and Safety of Substitution of Glucocorticoid for BDB-001 Injection in Patients With ANCA-associated Vasculitis
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (KarMMa-4)
Status: Completed, Estimated PCD: 2023-06-07
Clinical trial
A Phase 1/2, Open Label, Multicenter Trial to Assess the Safety and Efficacy of MB-102 in Patients With Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm
Status: Terminated, Estimated PCD: 2023-05-17
Clinical trial
Multicenter, Open-label, Adaptive Design Phase I Trial With Genetically Modified T-cells Carrying Universal Chimeric Antigen Receptors (UniCAR02-T) in Combination With CD123 Target Module (TM123) for the Treatment of Patients With Hematologic and Lymphatic Malignancies Positive for CD123
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized Phase II/III Study of αβ T Cell-Depleted, Related, Haploidentical Hematopoietic Stem Cell Transplant (Haplo-HSCT) Plus Rivogenlecleucel vs. Haplo-HSCT Plus Post-Transplant Cyclophosphamide (PTCy) in Patients With AML or MDS
Status: Terminated, Estimated PCD: 2019-07-23
Clinical trial
A Phase I/II Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination With Retifanlimab
Status: , Estimated PCD: 2024-06-30
Clinical trial
Phase 2b Single Arm Study of Maveropepimut-S and Low-Dose Cyclophosphamide in Subjects With Platinum-Resistant, Epithelial Ovarian Cancer.
Status: Terminated, Estimated PCD: 2023-07-24
Clinical trial
A Phase I/IIa Open Label, Non-Randomized, Multicenter Study of CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Aenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2023-02-15
Clinical trial
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone, in Combination With Lenalidomide or Oral Cyclophosphamide in Patients With Newly Diagnosed Multiple Myeloma
Status: Terminated, Estimated PCD: 2019-09-23
Clinical trial
A Phase Ib/II Study Evaluating the Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With B-Cell Non-Hodgkin's Lymphoma
Status: Completed, Estimated PCD: 2018-12-19
Clinical trial
A Single-Arm, Open-Label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR T Cell Therapy, And ALLO-647, An Anti-CD52 Monoclonal Antibody, in Patients With Relapsed/Refractory Large B-Cell Lymphoma or Follicular Lymphoma
Status: Active (not recruiting), Estimated PCD: 2021-10-23
Clinical trial
A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Status: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)
Status: Completed, Estimated PCD: 2022-11-15
Clinical trial
A Phase 1, Multicenter, Open-label Study of BMS-986403 in Subjects With Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Status: Terminated, Estimated PCD: 2023-05-04
Clinical trial
A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma (MM) Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib
Status: Completed, Estimated PCD: 2018-01-19
Clinical trial
Phase 1/2 Trial of TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Acute Lymphoblastic Leukemia (ALL)
Status: Completed, Estimated PCD: 2023-02-24
Clinical trial
A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination With Rituximab or Obinutuzumab in Subjects With Relapsed/Refractory B-cell Lymphoma and Chronic Lymphocytic Leukemia
Status: Terminated, Estimated PCD: 2023-09-27
Clinical trial
A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer
Status: Completed, Estimated PCD: 2023-08-14
Clinical trial
Relmacabtagene Autoleucel as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL: a Single-arm, Multicenter, Open, Phase II Study
Status: Not yet recruiting, Estimated PCD: 2024-08-01
Clinical trial
A Phase 1/2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adults With Refractory Aggressive Non-Hodgkin Lymphoma
Status: Completed, Estimated PCD: 2020-09-10
Clinical trial
Randomized, Parallel-group, Double-blind, Comparative Bioequivalence Trial of MabionCD20 Compared to MabThera (Rituximab by Hoffman-La Roche) in Patients With Diffuse Large B-cell Lymphoma
Status: Completed, Estimated PCD: 2017-08-01
Clinical trial
A Phase III, Randomized, Double-blind, Controlled Multicenter Study of Intravenous PI3K Inhibitor Copanlisib in Combination With Standard Immunochemotherapy Versus Standard Immunochemotherapy in Patients With Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL)
Status: Terminated, Estimated PCD: 2023-09-15
Clinical trial
A Phase 1b, Open-Label, Multicenter Study of FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
Status: Withdrawn, Estimated PCD: 2026-05-01
Clinical trial
Open-label, Single-arm Trial to Evaluate Antitumor Activity, Safety, and Pharmacokinetics of Isatuximab Used in Combination With Chemotherapy in Pediatric Patients From 28 Days to Less Than 18 Years of Age With Relapsed/Refractory B or T Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia in First or Second Relapse
Status: Terminated, Estimated PCD: 2022-09-12
Clinical trial
A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r ALL) (ZUMA-3)
Status: Completed, Estimated PCD: 2020-09-09
Clinical trial
Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma
Status: Completed, Estimated PCD: 2019-03-15
Clinical trial
A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Patients With Triple-Negative Breast Cancer
Status: Completed, Estimated PCD: 2023-03-08
Clinical trial
A Multicenter, Randomized, Phase II Clinical Trial to Evaluate the Effect of Avastin in Combination With Neoadjuvant Treatment Regimens on the Molecular and Metabolic Characteristics and Changes in the Primary Tumors With Reference to the Obtained Responses in Patients With Large Primary HER2 Negative Breast Cancers
Status: Completed, Estimated PCD: 2022-11-09
Clinical trial
A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma
Status: Terminated, Estimated PCD: 2023-10-23
Clinical trial
A Phase 1/2 Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma
Status: Terminated, Estimated PCD: 2021-05-07
Clinical trial
A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers
Status: Terminated, Estimated PCD: 2021-06-30
Clinical trial
A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or With Lenalidomide Plus R-CHOP (R2-CHOP) in Subjects With Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma
Status: Completed, Estimated PCD: 2022-04-24
Clinical trial
A Phase I, Open Label, Dose Escalation Study of ACE1702 Cell Immunotherapy in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase I Study of FT819 in Subjects With B-cell Malignancies
Status: Recruiting, Estimated PCD: 2024-09-30
Clinical trial
A Pilot Study of NY-ESO-1c259T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma
Status: Completed, Estimated PCD: 2021-11-01
Clinical trial
A Phase I, Open-Label, Multicenter Study of FT538 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-08-11
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Either Bendamustine and Rituximab (BR) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Previously Treated Indolent Non-Hodgkin Lymphoma (iNHL)
Status: Completed, Estimated PCD: 2022-05-30
Clinical trial
Phase 1 Trial of the LSD1 Inhibitor Seclidemstat (SP 2577) With and Without Topotecan and Cyclophosphamide in Patients With Relapsed or Refractory Ewing Sarcoma and Select Sarcomas
Status: Active (not recruiting), Estimated PCD: 2025-09-01
Clinical trial
A Phase 1/2a, Open-label, Dose-escalation, Dose-expansion Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed/Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2022-10-19
Clinical trial
A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-08-11
Clinical trial
Multi-center Phase I/II Study of NY-ESO-1 T Cell Receptor Gene Transferred T Lymphocytes in Patients With Synovial Sarcoma
Status: Completed, Estimated PCD: 2020-01-23
Clinical trial
A Phase 2 Multicenter Study Evaluating the Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Subjects With High-Risk Large B-Cell Lymphoma (ZUMA-12)
Status: Completed, Estimated PCD: 2021-05-17
Clinical trial
Clinical Study of Universal Off-the-shelf Cell Products in Patients With CD19-positive Relapsed/Refractory B-cell Hematolymphatic Malignancies.
Status: Not yet recruiting, Estimated PCD: 2026-07-01
Clinical trial
Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers That Progressed on PD-1/PD-L1 Inhibitors
Status: Recruiting, Estimated PCD: 2026-06-30
Clinical trial
Open-Label Phase 1b/2 Study of Sacituzumab Govitecan-Hziy Plus Chemoimmunotherapy for the Treatment of Subjects With Advanced Triple-Negative Breast Cancer After Prior Therapy
Status: Terminated, Estimated PCD: 2023-01-04
Clinical trial
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2020-07-14
Clinical trial
A Randomised, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in Patients With HER2+ Early Breast Cancer
Status: Completed, Estimated PCD: 2019-04-19
Clinical trial
A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2023-07-13
Clinical trial
A Phase 1 Multicenter Study of KITE-585, an Autologous Anti-BCMA CAR T-Cell Therapy, in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Terminated, Estimated PCD: 2018-12-17
Clinical trial
A Phase III, Randomized, Double-blind Study to Evaluate Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy for Triple Negative Breast Cancer (TNBC)
Status: Active (not recruiting), Estimated PCD: 2025-09-30
Clinical trial
Phase III Trial of TC Versus TAC in HER2-Negative Early Stage Breast Cancer Patients
Status: Completed, Estimated PCD: 2015-05-31
Clinical trial
A Single Dose-escalation Study to Evaluate the Safety and Efficacy of Allogeneic CAR-T Targeting CD19 Bridging Hematopoietic Stem Cell Transplantation in Patients With Refractory or Relapsed B Cell Acute Lymphoblastic Leukemia
Status: Not yet recruiting, Estimated PCD: 2025-01-22
Clinical trial
A Phase I, Open-Label, Multicenter Study of FT516 in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2023-08-11
Clinical trial
A Phase 1 Open-Label, Multi-Center Study of PSMA Targeted Genetically Modified Chimeric Antigen Receptor T Cells in Patients With Metastatic Castration Resistant Prostate Cancer
Status: Terminated, Estimated PCD: 2022-11-07
Clinical trial
Phase I Safety Study of Descartes-11 in Patients With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2024-02-06
Clinical trial
An Indian Multicentric Open Label Prospective Phase IV Study to Evaluate Safety and Efficacy of Trastuzumab in Her2 Positive, Node Positive or High Risk Node Negative Breast Cancer as Part of a Treatment Regimen Consisting of Doxorubicin, Cyclophosphamide, With Either Docetaxel or Paclitaxel (AC-TH) or Docetaxel and Carboplatin (TCH)
Status: Completed, Estimated PCD: 2021-06-24
Clinical trial
A Phase II Comparative, Open-Label, Randomized, Multicenter, China-Only Study to Investigate the Pharmacokinetics, Efficacy and Safety of Subcutaneous Rituximab Versus Intravenous Rituximab Both in Combination With CHOP in Previously Untreated Patients With CD20 Positive Diffuse Large B Cell Lymphoma
Status: Completed, Estimated PCD: 2022-05-23
Clinical trial
Phase 1/2a, Open-label, Dose-escalation, Dose-expansion, Parallel Assignment Study to Evaluate Safety and Clinical Activity of PBCAR0191 in Subjects With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
Status: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2027-09-01
Clinical trial
An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Status: Completed, Estimated PCD: 2022-09-22
Clinical trial
A Phase 2, Open-label, Single Arm, Multicohort, Multicenter Trial to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
Status: Active (not recruiting), Estimated PCD: 2028-09-28
Clinical trial
A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-647 and ALLO-605, an Anti- BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Status: Active (not recruiting), Estimated PCD: 2025-07-01
Clinical trial
Evaluation of Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
Status: Active (not recruiting), Estimated PCD: 2022-10-12
Clinical trial
A Phase 1 Multicenter Study Evaluating the Safety and Tolerability of KTE-X19 in Adult Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Status: Terminated, Estimated PCD: 2021-02-12
Clinical trial
Assessment of Safety and Recommended Phase 2 Dose of Autologous T Cells Engineered With an Affinity-enhanced TCR Targeting NYESO1 and LAGE1a, and Co-expressing CD8α (GSK3901961) in Participants With NYESO1 and/or LAGE1a Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma / Myxoid/Round Cell Liposarcoma; or NYESO1 and/or LAGE1a Positive Previously Treated Metastatic Non-Small Cell Lung Cancer
Status: Terminated, Estimated PCD: 2023-05-26
Clinical trial
A Prospective Multicenter Cohort Study of Outcome and Safety Profile of Risk Stratification Oriented Treatment in Pediatric Ewing Sarcoma in China
Status: Active (not recruiting), Estimated PCD: 2027-05-31
Clinical trial
Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Status: Recruiting, Estimated PCD: 2026-12-01
Clinical trial
European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
Status: Active (not recruiting), Estimated PCD: 2026-09-30
Clinical trial
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Patients With Hematologic Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-02-09
Clinical trial
Metronomic Chemotherapy in a Real-world Population of Advanced Breast Cancer Patients
Status: Completed, Estimated PCD: 2024-01-01
Clinical trial
Related and Unrelated Donor Hematopoietic Stem Cell Transplant for DOCK8 Deficiency
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Phase II Study of Split-Dose R-CHOP in Older Adults With Diffuse Large B-cell Lymphoma
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase II Trial of Reduced Intensity Conditioning and Partially HLA-mismatched (HLA-haploidentical) Related Donor Bone Marrow Transplantation for High-risk Solid Tumors
Status: Recruiting, Estimated PCD: 2027-01-01
Clinical trial
A Phase I-II Study of High-Dose Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD) Following Allogenic Hematopoietic Stem Cell Transplantation (HSCT)
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Status: Active (not recruiting), Estimated PCD: 2026-09-30
Clinical trial
N9: Pilot Study of Novel Shortened Induction Chemotherapy for High-Risk Neuroblastoma
Status: Recruiting, Estimated PCD: 2025-06-22
Clinical trial
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Status: Recruiting, Estimated PCD: 2025-06-01
Clinical trial
Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy and Ponatinib Followed by Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Status: Active (not recruiting), Estimated PCD: 2025-02-28
Clinical trial
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2022-08-04
Clinical trial
Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
Status: Completed, Estimated PCD: 2022-05-24
Clinical trial
Reduce Intensity Conditioning (RIC) Allogenic Hematopoietic Stem Cell Transplantation (Allo HSCT) for Patients With Relapsed Multiple Myeloma: A Pilot Study
Status: Terminated, Estimated PCD: 2021-05-08
Clinical trial
A Phase II Study Incorporating Bone Marrow Microenvironment (ME) - Co-Targeting Bortezomib Into Tandem Melphalan-Based Autotransplants With DTPACE for Induction/Consolidation and Thalidomide + Dexamethasone for Maintenance
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
Lead-In and Phase II Study of Clofarabine, Etoposide, Cyclophosphamide [CEC], Liposomal Vincristine (VCR), Dexamethasone and Bortezomib in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
Status: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
Phase 1 Study of Autologous Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13R alpha2 CAR (E-SYNC) T Cells in Adult Participants With EGFRvIII+ Glioblastoma
Status: Recruiting, Estimated PCD: 2030-05-31
Clinical trial
Administration of Her2 Chimeric Antigen Receptor Expressing T Cells for Subjects With Advanced Sarcoma (HEROS)
Status: Active (not recruiting), Estimated PCD: 2019-12-06
Clinical trial
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Clinical Study to Evaluate the Possible Safety and Efficacy of Fenofibrate in the Prophylaxis of Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
MUK Nine b: OPTIMUM. A Phase II Study Evaluating Optimised Combination of Biological Therapy in Newly Diagnosed High Risk Multiple Myeloma and Plasma Cell Leukaemia.
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Clinical trial
Allogeneic TRAC Locus-inserted CD19-targeting Synthetic T-cell Receptor Antigen Receptor (STAR) T Cells for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Status: Recruiting, Estimated PCD: 2026-03-20
Clinical trial
Pilot Study of JAK Inhibitor Therapy Followed by Reduced Intensity Haploidentical Transplantation for Patients With Myelofibrosis
Status: Recruiting, Estimated PCD: 2024-08-31
Clinical trial
Pilot Study: Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (Dilanubicel) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2024-10-08
Clinical trial
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Status: Active (not recruiting), Estimated PCD: 2026-10-31
Clinical trial
Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma
Status: Completed, Estimated PCD: 2015-05-01
Clinical trial
A Randomised Phase IIb Trial of Bevacizumab Added to Temozolomide ± Irinotecan for Children With Refractory/Relapsed Neuroblastoma - BEACON-Neuroblastoma Trial
Status: Active (not recruiting), Estimated PCD: 2021-08-01
Clinical trial
a 3 Arm Randomized Study on Health-related Quality of Life of Elderly Patients With Advanced Soft Tissue Sarcoma Undergoing Doxorubicin Alone Every Three Weeks or Doxorubicin Weekly or Cyclophosphamide Plus Predniso(lo)ne Treatment
Status: Terminated, Estimated PCD: 2023-09-22
Clinical trial
CARTIMMUNE: A Single-Center Study of Patients With Autoimmune Diseases Receiving an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (KYV 101)
Status: Not yet recruiting, Estimated PCD: 2028-06-01
Clinical trial
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Allogeneic Hematopoietic Stem Cell Transplantation as Initial Salvage Therapy for Patients With Primary Induction Failure Acute Myeloid Leukemia Refractory to High-Dose Cytarabine-Based Induction Chemotherapy
Status: Completed, Estimated PCD: 2020-09-22
Clinical trial
Phase I/II Study of Pan-T Booster Co-expressing MSLN CAR T Cell Therapy in Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Treatment Regimen or Children or Adolescent With Mature B-cell NHL or B-AL in China
Status: Active (not recruiting), Estimated PCD: 2023-12-31
Clinical trial
A Multicentre, Open-label, Randomised Trial of Neoadjuvant Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer
Status: Recruiting, Estimated PCD: 2024-10-30
Clinical trial
A Phase I Study of Adoptive Immunotherapy for Advanced B-Cell Maturation Antigen (BCMA)+ Multiple Myeloma With Autologous CD4+ and CD8+ T Cells Engineered to Express a BCMA-Specific Chimeric Antigen Receptor
Status: Completed, Estimated PCD: 2021-05-03
Clinical trial
Phase 1 Study of Copanlisib With Dose-adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
Status: Completed, Estimated PCD: 2023-11-30
Clinical trial
Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic Chemotherapy of Vinorelbine, Cyclophosphamide and Capecitabine (VEX) Regime in Advanced Triple-negative Breast Cancer: a Multicenter, Randomized, Phase II Study
Status: Not yet recruiting, Estimated PCD: 2025-01-19
Clinical trial
A Phase I Trial of B-cell Maturation Antigen (BCMA) Targeted EGFRt/BCMA-41BBz Chimeric Antigen Receptor (CAR) Modified T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma (MM)
Status: Active (not recruiting), Estimated PCD: 2025-02-01
Clinical trial
A Phase 1 Study of Autologous Activated T-cells Targeting the B7-H3 Antigen in Subjects With Recurrent Epithelial Ovarian Cancer
Status: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
Phase II Study of Combination of Hyper-CVAD and Ponatinib in Patients With Philadelphia (PH) Chromosome Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)
Status: Active (not recruiting), Estimated PCD: 2025-10-31
Clinical trial
An Open-label Phase II Trial Evaluating the Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in Early-stage Triple-negative Breast Cancer（NeoSACT）
Status: Recruiting, Estimated PCD: 2023-08-31
Clinical trial
Treatment Protocol for Newky Diagnosed Adult Ph-Chromosome Positive (BCR::ABL1) Acute Lymphoblastic Leukemia (LALPh2022)
Status: Not yet recruiting, Estimated PCD: 2028-12-25
Clinical trial
A Pilot Study of Reduced Intensity HLA-Haploidentical Hematopoietic Cell Transplantation With Post-Transplant Cyclophosphamide in Patients With Advanced Myelofibrosis
Status: Recruiting, Estimated PCD: 2025-03-24
Clinical trial
N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan for Patients With Relapsed or Refractory Neuroblastoma
Status: Active (not recruiting), Estimated PCD: 2023-12-30
Clinical trial
A Study of T-Cell Replete, HLA-Mismatched Haploidentical Bone Marrow Transplantation With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia Lacking HLA-Matched Related Donor
Status: Recruiting, Estimated PCD: 2025-08-31
Clinical trial
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
Status: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Randomized Phase II Trial of Metronomic Oral Vinorelbine Plus Cyclophosphamide and Capecitabine (VEX) Versus Weekly Paclitaxel as First-line or Second-line Treatment in Patients With ER-positive/HER2-negative Advanced or Metastatic Breast Cancer
Status: Completed, Estimated PCD: 2021-11-17
Clinical trial
RAVEN: A Phase I/II Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax
Status: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
A Phase I Clinical Trial With TriPRIL CAR T Cells for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Phase 2 Study of an Immune Therapy, DPX-Survivac With Low Dose Cyclophosphamide Administered With Pembrolizumab in Patients With Persistent or Recurrent/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Status: Completed, Estimated PCD: 2021-10-31
Clinical trial
A Phase I Trial Using In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies
Status: Active (not recruiting), Estimated PCD: 2026-09-01
Clinical trial
A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Disease and Other Hemoglobinopathies
Status: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
Phase II Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Status: Completed, Estimated PCD: 2023-06-12
Clinical trial
Comparing Post-Transplant Cyclophosphamide With Calcineurin Inhibitors as A GVHD Prophylaxis to Standard Care of Methotrexate and Calcineurin Inhibitors for Acute Leukemia Incorporating Patient Pharmacogenomics Profiling
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
A Phase I/II Dose Escalation, Safety and Efficacy Study of Anti-NY-ESO-1 T Cell Receptor (TCR)-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Status: Recruiting, Estimated PCD: 2027-12-30
Clinical trial
Siplizumab-based Conditioning for Hematopoietic Stem Cell Transplantation in Patients With Advanced Sickle Cell Disease (CD2 SCD)
Status: Recruiting, Estimated PCD: 2028-07-01
Clinical trial
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Mutations in GATA2 or the MonoMAC Syndrome
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Early Immunotherapy With Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients With Anti-Hu-associated Paraneoplastic Sensory Neuronopathy
Status: Not yet recruiting, Estimated PCD: 2027-06-01
Clinical trial
MT2017-17:T Cell Receptor Alpha/Beta T Cell Depleted Hematopoietic Cell Transplantation in Patients With Inherited Bone Marrow Failure (BMF) Disorders
Status: Recruiting, Estimated PCD: 2026-01-01
Clinical trial
Phase 1b/2a Trial of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) From an HLA-partially Matched Related or Unrelated Donor After TCRαβ+ T-cell/CD19+ B-cell Depletion for Patients Who Will Receive a Kidney Transplant (KT) From the Same HSCT/KT Donor
Status: Recruiting, Estimated PCD: 2032-10-01
Clinical trial
A Phase 3, Intergroup Multicentre, Randomized, Controlled 3 Arm Parallel Group Study to Determine the Efficacy and Safety of Lenalidomide in Combination With Dexamethasone (RD) Versus Melphalan, Prednisone and Lenalidomide (MPR) Versus Cyclophosphamide, Prednisone and Lenalidomide (CPR) in Newly Diagnosed Elderly Multiple Myeloma Subjects
Status: Active (not recruiting), Estimated PCD: 2012-11-01
Clinical trial
Phase Ib Study to Test the Feasibility and Safety of a Personalized Vaccine in Combination With Low-dose Cyclophosphamide in Patients With Advanced or Metastatic Non Small Cell Lung Cancer (NSCLC)
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Phase I/II Study to Test the Immunogenicity, Feasibility, and Safety of Autologous PEP-DC Vaccine vs. Autologous OC-DC Vaccine Followed by PEP-DC Vaccine, in Combination With Low-dose Cyclophosphamide, in Patients With Advanced HGSOC
Status: Not yet recruiting, Estimated PCD: 2030-03-01
Clinical trial
Nivolumab and Oral Cyclophosphamide for Relapsed/Refractory Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndrome (MDS)
Status: Completed, Estimated PCD: 2022-01-25
Clinical trial
Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders
Status: Withdrawn, Estimated PCD: 2023-09-18
Clinical trial
LET+CTX
Status: Completed, Estimated PCD: 2020-12-01
Clinical trial
G-CSF+DAC+BUCY vs. G-CSF+DAC+BF Conditioning Regimen for Patients With High-risk MDS Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
Phase IIA Basket Study of Pixatimod (PG545) in Combination With Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and Pixatimod (PG545) in Combination With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)
Status: Completed, Estimated PCD: 2024-02-05
Clinical trial
Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy
Status: Active (not recruiting), Estimated PCD: 2020-06-23
Clinical trial
A Phase I Trial of T-Lymphocytes Genetically Targeted to the B-Cell Specific Antigen CD19 in Pediatric and Young Adult Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
Status: Active (not recruiting), Estimated PCD: 2025-05-01
Clinical trial
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity
Status: Recruiting, Estimated PCD: 2026-10-01
Clinical trial
A Phase II Study of Allogeneic Hematopoietic Stem Cell Transplant for Subjects With VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome
Status: , Estimated PCD: 2026-07-01
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10272
Abstract
https://www.abstractsonline.com/pp8/#!/20272/presentation/11873
Clinical trial
A Phase III, Randomized, Open, Parallel-controlled, Multi-center Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis
Status: Completed, Estimated PCD: 2018-09-10
Organization
Hikma Pharmaceuticals USA Inc.
Organization
AuroMedics Pharma LLC
Organization
NORTHSTAR RX LLC
Document
DailyMed Label: Cyclophosphamide
Organization
Sandoz Inc.
Organization
BluePoint Laboratories
Organization
Baxter Healthcare Corporation
Organization
Alembic Pharmaceuticals Inc.
Organization
Sagent Pharmaceuticals
Organization
Nevakar Injectables Inc.
Organization
Eugia US LLC
Organization
Fresenius Kabi USA, LLC
Organization
Ingenus Pharmaceuticals, LLC
Organization
Athenex Pharmaceutical Division, LLC.
Organization
Dr. Reddy's Labratories Inc.
Organization
NorthStar RxLLC
Organization
Cipla USA Inc.
Organization
Amneal Pharmaceuticals LLC
Organization
Dr. Reddy's Laboratories Inc.
Organization
Alembic Pharmaceuticals Limited
Organization
Avyxa Pharma, LLC
Organization
STI Pharma LLC
Organization
Civica, Inc.
Organization
Golden State Medical Supply, Inc.
Organization
Baxter Healthcare Corporation
Organization
XGen Pharmaceuticals DJB, Inc.
Organization
Bamboo US Bidco LCC
Organization
Long Grove Pharmaceuticals, LLC